Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin Pharmaceutical is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.

With the acquisition, BioMarin adds Galafold for Fabry disease and Pombiliti+Opfolda for Pompe disease.

Case Western Reserve University School of Law Co-Dean Michael Scharf will present an Amicus argument before the Appeals Chamber of the International Criminal Court (ICC) in The Hague on Feb. 14 from 8 ...

An Amicus Therapeutics combination treatment for the rare enzyme deficiency Pompe disease now has FDA approval, giving the drugmaker the opportunity to help patients who don’t respond to Sanofi ...

"If you don't require leave of court," amici could file briefs to target the recusal of a certain judge, Ninth Circuit Judge Sidney Thomas said. A judiciary rules committee is weighing whether it ...

Amicus O&M Cooperative has launched an online course to advance solar and battery storage O&M technicians from supervised helpers to well-rounded ...

Amicus curiae briefs are deeply woven into the fabric of modern federal appellate practice. Indeed, amici curiae submit briefs in approximately ninety percent of the cases that the United States ...

The Solar PV and BESS O&M Tech 2 program satisfies the educational requirements for NABCEP’s PV Commissioning and Maintenance Specialist certification and fulfills all continuing education ...